Association of soft drinks and 100% fruit juice consumption with risk of cancer: a systematic review and dose-response meta-analysis of prospective cohort studies.
Artificially sweetened beverages
Dose–response meta-analysis
Fruit juices, Cancer
Sugar-sweetened beverages
Journal
The international journal of behavioral nutrition and physical activity
ISSN: 1479-5868
Titre abrégé: Int J Behav Nutr Phys Act
Pays: England
ID NLM: 101217089
Informations de publication
Date de publication:
15 05 2023
15 05 2023
Historique:
received:
26
07
2022
accepted:
26
04
2023
medline:
17
5
2023
pubmed:
16
5
2023
entrez:
15
5
2023
Statut:
epublish
Résumé
Studies of the associations between soft drinks and the risk of cancer showed inconsistent results. No previous published systematic reviews and meta-analysis has investigated a dose-response association between exposure dose and cancer risk or assessed the certainty of currently available evidence. Therefore, we aim to demonstrate the associations and assessed the certainty of the evidence to show our confidence in the associations. We searched Embase, PubMed, Web of Science, and the Cochrane Library from inception to Jun 2022, to include relevant prospective cohort studies. We used a restricted cubic spline model to conduct a dose-response meta-analysis and calculated the absolute effect estimates to present the results. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of the evidence. Forty-two articles including on 37 cohorts enrolled 4,518,547 participants were included. With low certainty evidence, increased consumption of sugar-sweetened beverages (SSBs) per 250 mL/day was significantly associated with a 17% greater risk of breast cancer, a 10% greater risk of colorectal cancer, a 30% greater risk of biliary tract cancer, and a 10% greater risk of prostate cancer; increased consumption of artificially sweetened beverages (ASBs)re per 250 mL/day was significantly associated with a 16% greater risk of leukemia; increased consumption of 100% fruit juice per 250 mL/day was significantly associated with a 31% greater risk of overall cancer, 22% greater risk of melanoma, 2% greater risk of squamous cell carcinoma, and 29% greater risk of thyroid cancer. The associations with other specific cancer were no significant. We found linear dose-response associations between consumption of SSBs and the risk of breast and kidney cancer, and between consumption of ASBs and 100% fruit juices and the risk of pancreatic cancer. An increment in consumption of SSBs of 250 mL/day was positively associated with increased risk of breast, colorectal, and biliary tract cancer. Fruit juices consumption was also positively associated with the risk of overall cancer, thyroid cancer, and melanoma. The magnitude of absolute effects, however, was small and mainly based on low or very low certainty of evidence. The association of ASBs consumption with specific cancer risk was uncertain. PROSPERO: CRD42020152223.
Sections du résumé
BACKGROUND
Studies of the associations between soft drinks and the risk of cancer showed inconsistent results. No previous published systematic reviews and meta-analysis has investigated a dose-response association between exposure dose and cancer risk or assessed the certainty of currently available evidence. Therefore, we aim to demonstrate the associations and assessed the certainty of the evidence to show our confidence in the associations.
METHODS
We searched Embase, PubMed, Web of Science, and the Cochrane Library from inception to Jun 2022, to include relevant prospective cohort studies. We used a restricted cubic spline model to conduct a dose-response meta-analysis and calculated the absolute effect estimates to present the results. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of the evidence.
RESULTS
Forty-two articles including on 37 cohorts enrolled 4,518,547 participants were included. With low certainty evidence, increased consumption of sugar-sweetened beverages (SSBs) per 250 mL/day was significantly associated with a 17% greater risk of breast cancer, a 10% greater risk of colorectal cancer, a 30% greater risk of biliary tract cancer, and a 10% greater risk of prostate cancer; increased consumption of artificially sweetened beverages (ASBs)re per 250 mL/day was significantly associated with a 16% greater risk of leukemia; increased consumption of 100% fruit juice per 250 mL/day was significantly associated with a 31% greater risk of overall cancer, 22% greater risk of melanoma, 2% greater risk of squamous cell carcinoma, and 29% greater risk of thyroid cancer. The associations with other specific cancer were no significant. We found linear dose-response associations between consumption of SSBs and the risk of breast and kidney cancer, and between consumption of ASBs and 100% fruit juices and the risk of pancreatic cancer.
CONCLUSIONS
An increment in consumption of SSBs of 250 mL/day was positively associated with increased risk of breast, colorectal, and biliary tract cancer. Fruit juices consumption was also positively associated with the risk of overall cancer, thyroid cancer, and melanoma. The magnitude of absolute effects, however, was small and mainly based on low or very low certainty of evidence. The association of ASBs consumption with specific cancer risk was uncertain.
TRIAL REGISTRATION
PROSPERO: CRD42020152223.
Identifiants
pubmed: 37189146
doi: 10.1186/s12966-023-01459-5
pii: 10.1186/s12966-023-01459-5
pmc: PMC10184323
doi:
Substances chimiques
Sweetening Agents
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
58Informations de copyright
© 2023. The Author(s).
Références
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1204-11
pubmed: 16775182
BMJ. 2016 Jan 06;352:h6704
pubmed: 26738745
Cancer Epidemiol. 2021 Feb;70:101855
pubmed: 33220638
Br J Nutr. 2018 Sep;120(6):703-710
pubmed: 30047347
Int J Cancer. 2018 May 1;142(9):1748-1758
pubmed: 29210053
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Carcinogenesis. 2015 Oct;36(10):1162-8
pubmed: 26224304
Am J Clin Nutr. 2016 Sep;104(3):760-8
pubmed: 27510540
BMJ. 2019 Jul 10;366:l2408
pubmed: 31292122
BMJ. 2015 Jul 21;351:h3576
pubmed: 26199070
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Am J Gastroenterol. 2019 Dec;114(12):1870-1877
pubmed: 31688024
Circulation. 2015 Aug 25;132(8):639-66
pubmed: 26124185
Lancet. 2017 Sep 16;390(10100):1345-1422
pubmed: 28919119
Am J Clin Nutr. 2022 Jun 7;115(6):1481-1489
pubmed: 35470384
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Eur J Epidemiol. 2011 Aug;26(8):589-93
pubmed: 21796419
Diabetes. 2013 Oct;62(10):3307-15
pubmed: 24065788
Biomed Res Int. 2015;2015:128697
pubmed: 25695045
Public Health Nutr. 2018 Jun;21(9):1618-1626
pubmed: 29463332
Am J Clin Nutr. 2020 Nov 11;112(5):1267-1279
pubmed: 32936868
Am J Clin Nutr. 2012 Dec;96(6):1419-28
pubmed: 23097267
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Physiol Behav. 2012 Nov 5;107(4):560-7
pubmed: 22583859
Am J Clin Nutr. 2007 Nov;86(5):1495-501
pubmed: 17991664
Eur J Cancer Prev. 2014 Sep;23(5):481-90
pubmed: 24625472
Pediatr Obes. 2016 Jun;11(3):221-7
pubmed: 26110996
Diabetes Care. 2019 Dec;42(12):2181-2189
pubmed: 31582428
Int J Cancer. 2011 Jun 1;128(11):2695-708
pubmed: 20715171
Br J Cancer. 2011 Apr 26;104(9):1487-92
pubmed: 21407222
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):447-55
pubmed: 20142243
PLoS One. 2019 Oct 9;14(10):e0223638
pubmed: 31596902
Eur J Nutr. 2019 Oct;58(7):2875-2886
pubmed: 30284064
FASEB J. 1990 Jun;4(9):2652-60
pubmed: 2189777
QJM. 2017 Aug 01;110(8):513-520
pubmed: 28402535
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2098-105
pubmed: 16172216
J Clin Epidemiol. 2011 Dec;64(12):1311-6
pubmed: 21802902
Am J Clin Nutr. 2006 Nov;84(5):1171-6
pubmed: 17093171
Eur J Cancer. 2010 Jul;46(10):1873-81
pubmed: 20395127
Am J Clin Nutr. 2009 Jan;89(1):1-14
pubmed: 19056571
Eur J Nutr. 2016 Feb;55(1):7-20
pubmed: 25528243
Am J Clin Nutr. 2012 Dec;96(6):1409-18
pubmed: 23134882
J Nutr. 2021 Sep 4;151(9):2768-2779
pubmed: 34114021
Cancer Prev Res (Phila). 2018 Jun;11(6):347-358
pubmed: 29674390
Nutrients. 2021 Feb 04;13(2):
pubmed: 33557387
Am J Epidemiol. 2012 Jan 1;175(1):66-73
pubmed: 22135359
J Clin Epidemiol. 2021 Jul;135:17-28
pubmed: 33657455
Int J Cancer. 2018 Feb 1;142(3):449-459
pubmed: 28688112
Cancer Causes Control. 2011 Jan;22(1):33-9
pubmed: 20981481
Eur J Cancer Prev. 2000 Apr;9(2):125-30
pubmed: 10830580
Am J Epidemiol. 1992 Jun 1;135(11):1301-9
pubmed: 1626547
Pediatrics. 2017 Jun;139(6):
pubmed: 28562300
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Adv Nutr. 2021 Feb 1;12(1):89-101
pubmed: 32696948
Gut. 2021 Dec;70(12):2330-2336
pubmed: 33958435
Proc Nutr Soc. 2012 Feb;71(1):181-9
pubmed: 22051112
PLoS Med. 2020 Jul 28;17(7):e1003224
pubmed: 32722677
J Am Coll Cardiol. 2015 Oct 6;66(14):1615-1624
pubmed: 26429086
Front Oncol. 2022 Apr 07;12:835901
pubmed: 35463371
J Nutr. 2014 Dec;144(12):2041-9
pubmed: 25342696
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1270-1274
pubmed: 33849969
Am J Clin Nutr. 2008 Aug;88(2):431-40
pubmed: 18689380
Arch Cardiovasc Dis. 2016 Apr;109(4):242-53
pubmed: 26869455
J Nutr. 2015 Mar;145(3):595-604
pubmed: 25733477
Am J Clin Nutr. 2010 Dec;92(6):1429-35
pubmed: 21097651
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2384-94
pubmed: 24273064
Int J Cancer. 2020 Jun 15;146(12):3329-3334
pubmed: 31693185
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1831-7
pubmed: 21765006
J Natl Cancer Inst. 2010 Jun 2;102(11):771-83
pubmed: 20453203
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583
J Clin Oncol. 2015 Aug 10;33(23):2500-8
pubmed: 26124488
N Engl J Med. 1999 May 6;340(18):1390-7
pubmed: 10228189